Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Restructuring
Aurobindo Pharma's board has approved a Scheme of Amalgamation for the merger of two step-down wholly-owned subsidiaries, Eugia Steriles and Eugia SEZ, with Eugia Pharma Specialities. This internal restructuring aims to simplify the group structure, consolidate similar businesses, reduce overheads, and achieve synergy benefits.
Aug 05 2026 20:09:34
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Aurobindo Pharma reported robust Q1 FY27 consolidated results, with revenue increasing 16.3% YoY to Rs.9,150 Cr and net profit rising 25.2% YoY to Rs.1,032 Cr. EBITDA margin stood at 21.0%, up 60 bps YoY, reflecting strong operational performance.
Aug 05 2026 20:02:52
Aurobindo Pharma Ltd - 524804 - Board Meeting Outcome for Outcome Of The Board Meeting Held On August 5, 2026
Aurobindo Pharma's board approved Q1 FY27 cons. financial results, reporting revenue of ₹9,150.35 cr (up 16.3% YoY) and net profit of ₹1,032.03 cr (up 25.2% YoY). Additionally, a scheme for amalgamation of three wholly-owned subsidiaries, Eugia Steriles, Eugia SEZ, and Eugia Pharma Specialities Limited, was approved, pending NCLT filing.
Aug 05 2026 19:52:54
Aurobindo Pharma Ltd - 524804 - Board Meeting Intimation for Intimation Of Board Meeting.
Aurobindo Pharma's Board of Directors will meet on August 5, 2026, to consider and approve the standalone and consolidated unaudited financial results for the first quarter ended June 30, 2026. This meeting is a routine quarterly update for investors.
Jul 27 2026 18:20:20
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Aurobindo Pharma signed a non-exclusive voluntary license agreement with MSD to supply generic alimatravir for HIV prevention. This royalty-free agreement targets 129 Low- & Middle-Income Countries, expanding access to crucial medicines.
Jul 24 2026 21:44:58
Aurobindo Pharma Ltd - 524804 - ANVISA Approval For Curateq Biologics'' Biosimilars Manufacturing Facility
Aurobindo Pharma's subsidiary, CuraTeQ Biologics Private Limited, has received approval from ANVISA for its biosimilars manufacturing facility in Hyderabad. This approval, following a GMP inspection, strengthens the company's capability to supply biosimilar products to the Brazilian and broader Latin American markets.
Jul 21 2026 16:29:36
Read More